Oppenheimer raised the firm’s price target on Cigna to $400 from $370 and keeps an Outperform rating on the shares. Cigna reported strong Q1 results, driven by a solid medical cost ratio beat due to broad commercial strength, where IP claims were elevated but in line with expectations, the analyst tells investors in a research note. Cigna continues to be one of the most consistent performers in the space, and Oppenheimer is a buyer after another solid quarter.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- CI Earnings: Cigna Rises on Strong Q1 Performance
- Cigna raises FY24 adjusted EPS view to $28.40 from $28.25, consensus $28.43
- Cigna reports Q1 adjusted EPS $6.47, consensus $6.22
- The Cigna Group Reports Strong First Quarter 2024 Results, Raises 2024 Outlook
- Notable companies reporting before tomorrow’s open